Skip to content

A Prospective Clinical and Radiographic Assessment on New Platform-switched Laser Lok Implants

A Prospective Clinical and Radiographic Assessment on New Platform-switched Laser Lok Implants

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01899131
Enrollment
10
Registered
2013-07-15
Start date
2013-10-31
Completion date
2016-06-30
Last updated
2014-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preserve Crestal Bone Level and Gingival Margin Around Dental Implants

Keywords

dental implants, crestal bone, gingival margin

Brief summary

1. To investigate the hard and soft tissue adaptation and maintenance to the Laser-Lok® microchannels permanent abutment/ new Laser-Lok® implant assembly by performing clinical and radiographic evaluations. 2. To investigate the effect of inter-implant spacing (minimum of 2 or 3 mm) on hard and soft tissues. 3. To perform clinical and radiographic evaluations on these abutment/implant assemblies up to 2 years.

Detailed description

* Screening (Inclusion/ Exclusion Criteria) * Day of Surgery: Dental CT scan/ periapical radiograph / clinical picture / clinical examination (probing depth, BOP, gingival recession). * Implant Restoration Day: Post-restoration periapical radiograph/ clinical picture/ clinical examination (probing depth, BOP, gingival recession). * 6 month, 1 Year and 2 Year Post Restoration: periapical radiograph / clinical picture / clinical examination (probing depth, BOP, gingival recession).

Interventions

DEVICEplatform-switch tapered internal implants

Laser-Lok permanent abutment/ new Laser Lok platform-switch implant assembly.assessment at 6,12,24 month clinicaly and radiographic

Sponsors

Tel-Aviv Sourasky Medical Center
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

1. Male or female, between 20-70 years of age, who request dental implant treatment options for rehabilitation. 2\. Subjects who are willing to sign an informed consent, participate and return for follow-up visits. 3\. Subjects without significant medical history and currently not on medications that might complicate the results. 4\. Subjects presenting with an edentulous area requiring a tooth-replacement option. \-

Exclusion criteria

1. Subjects who do not meet all the inclusion criteria or who will not cooperate with the protocol schedule. 2\. Subjects who received and failed a previously placed dental implant. 3. Subjects who require an onlay ridge augmentation procedure in the area to achieve adequate bone volume for the placement of dental implants. 4\. Subjects who have significant untreated periodontal disease, caries, infection or chronic inflammation in the oral cavity within two adjacent tooth positions of the clinical trial area. 5\. Subjects who have used nicotine-containing products within 3 weeks prior to surgery. 6\. Subjects who are insulin-dependent diabetic or if their Hgb1c levels \> 6.5%. 7. Subjects who have had a history of malignancy within the past 5 years (except for basal or squamous cell carcinoma of the skin or in situ cervical carcinoma). 8\. Subjects who are nursing or pregnant. 9. Subjects who are presently taking medications (except estrogen/progesterone therapy) or those who are undergoing treatment that in known to have an effect on bone turnover. 10\. Subjects who have diseases that affect bone metabolism (excluding idiopathic osteoporosis). 11\. Subjects with a history of an autoimmune disease, documented allergy or multiple allergies to any component of the agents used in this study. 12\. Acutely infected defect site. 13. Immediate implant site. \-

Design outcomes

Primary

MeasureTime frameDescription
epithelial attachment and bone level around implants2 yearsprevent apical migration of the epithelial attachment, and preserve bone level around implant head. radiographic and clinical assessment during recall periods

Secondary

MeasureTime frameDescription
inhibit the loss of crestal bone .2 yearspreserve the coronal level of bone

Countries

Israel

Contacts

Primary ContactAmnon Singer, DMD
amnons@tlvmc.gov.il+97236973676

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026